contentSlug

type

ContentSlug_ContentQuery

slug

ContentPageContentQuery

content

trendingContent

query ContentSlug_ContentQuery(
  $contentSlug: String!
  $type: [ContentType!]
) {
  ...ContentPageContentQuery_13QmVO
}

fragment CompanyDetails_Content on Content {
  __isContent: __typename
  companies {
    name
    description
    pageUrl
    id
  }
}

fragment CompanyTagList on Company {
  pageUrl
  name
  viewerIsFollowing
}

fragment ContentBasicInfo on Content {
  __isContent: __typename
  id
  type
  title
  lang
  companies {
    ...CompanyTagList
    id
  }
  ...PublishingDetails
  ...Reactions
}

fragment ContentMetadata on Content {
  __isContent: __typename
  type
  title
  lang
  pageUrl
  alternatePageUrls {
    pageUrl
    lang
  }
  imgUrl
  description
  ... on Video {
    liveTime
    videoUrl
  }
  ... on Webcast {
    liveTime
    videoUrl
  }
}

fragment ContentPageContentQuery_13QmVO on Query {
  content(slug: $contentSlug, type: $type) {
    __typename
    id
    type
    title
    isPremium
    lang
    htmlBody
    companies {
      forum {
        latestPosts {
          ...ForumPosts
        }
      }
      defaultInstrument {
        isin
        id
      }
      id
    }
    slug
    ... on CompanyReport {
      reportUrl
    }
    ... on ThirdPartyCompanyReport {
      reportUrl
    }
    ... on StockExchangeRelease {
      reportUrl
    }
    ...ContentBasicInfo
    ...ContentMetadata
    ...PriceAndRecommendation_Content
    ...CompanyDetails_Content
    ...ReportLink_Content
    ...KeyFigures_Content
  }
  ...TrendingContent_1jQ2Cn
}

fragment ForumPosts on ForumPost {
  text
  likesCount
  url
  author
  postedAt
  authorImgUrl
}

fragment KeyFigures_Content on Content {
  __isContent: __typename
  companies {
    defaultInstrument {
      estimateData {
        modelType
        reportingCurrency
      }
      snapshot {
        transaction {
          date
          actualized {
            year
            quarter
            revenue
            revenueGrowth
            ebitAdjusted
            ebitReported
            ebitda
            enterpriseValue
            epsAdjusted
            dividend
            dividendYield
            sharePrice
          }
          estimates {
            year
            quarter
            revenue
            revenueGrowth
            ebitAdjusted
            ebitReported
            ebitda
            enterpriseValue
            epsAdjusted
            dividend
            dividendYield
            sharePrice
          }
        }
      }
      id
    }
    id
  }
}

fragment PriceAndRecommendation_Content on Content {
  __isContent: __typename
  createdAt
  companies {
    id
    name
    viewerIsFollowing
    defaultInstrument {
      snapshot {
        priceData {
          date
          lastPrice
          tradeCurrency
        }
        transaction {
          date
          recommendation
          targetPrice
        }
        prevTransaction {
          recommendation
        }
      }
      id
    }
  }
}

fragment PublishingDetails on Content {
  __isContent: __typename
  createdAt
  publishers {
    name
    imgUrl
  }
  authors {
    __typename
    id
    name
    slug
    imgUrl
    jobTitle
  }
  ... on Video {
    liveTime
  }
  ... on Webcast {
    liveTime
  }
}

fragment Reactions on Content {
  __isContent: __typename
  id
  reactionGroups {
    reactionType
    reactionsCount
    viewerReacted
  }
}

fragment ReportLink_Content on Content {
  __isContent: __typename
  type
  isPremium
  ... on CompanyReport {
    reportUrl
  }
  ... on ThirdPartyCompanyReport {
    reportUrl
  }
  ... on StockExchangeRelease {
    reportUrl
  }
}

fragment TrendingContent_1jQ2Cn on Query {
  trendingContent(type: ARTICLE) {
    __typename
    id
    title
    lang
    pageUrl
    createdAt
    type
    imgUrl
    companies {
      squareLogoUrl
      id
    }
    authors {
      __typename
      imgUrl
      id
    }
    publishers {
      imgUrl
    }
  }
}


invitation-to-presentation-of-bioinvents-interim-report-january-september-2024

__typename

title

isPremium

lang

htmlBody

companies

createdAt

publishers

authors

reactionGroups

pageUrl

alternatePageUrls

imgUrl

description

BioInvent International är verksamt inom läkemedelsindustrin. Bolaget fokuserar på forskning och utveckling av antikroppsläkemedel som används i behandling mot cancertillstånd. Bolaget har en egen utvecklad utvecklingsplattform och samarbeten sker via bolagets partners. I tidig utvecklingsfas arbetar bolaget med att återskapa sjukdomsbiologin för att få indikationer om substansernas effekt på sjukdomen. Huvudkontoret ligger i Lund.

BioInvent International

Lund, Sweden, October 29, 2024– BioInvent International AB (“BioInvent”) (Nasdaq Stockholm: BINV) invites investors, analysts and the press to a presentation of the interim report January- September...

<div class="mfn-body">Lund, Sweden, October 29, 2024– BioInvent International AB (“BioInvent”) (Nasdaq Stockholm: BINV) invites investors, analysts and the press to a presentation of the interim report January- September 2024 at 5:00 pm CET on Thursday October 31. The report will be published at 8:00 am CET the same day.BioInvent’s CEO Martin Welschof will present the report together with CFO Stefan Ericsson. The presentation will be held in English.When: Thursday October 31, 2024, at 5:00 pm CETIf you wish to participate via webcast, please use the link below. Via the webcast you&nbsp;are able to&nbsp;ask written questions. <a rel="noopener" href="https://ir.financialhearings.com/bioinvent-q3-report-2024">https://ir.financialhearings.com/bioinvent-q3-report-2024</a>If you wish to participate via teleconference, please register on the link below. After registration you will be provided with phone numbers and a conference ID to access the conference. You can ask questions verbally via the teleconference. <a rel="noopener" href="https://conference.financialhearings.com/teleconference/?id=50048633">https://conference.financialhearings.com/teleconference/?id=50048633</a>The conference call will be made available on the company website after the call.About BioInvent BioInvent International AB (Nasdaq Stockholm: BINV) is a clinical-stage biotech company that discovers and develops novel and first-in-class immuno-modulatory antibodies for cancer therapy, with currently five drug candidates in six ongoing clinical programs in Phase 1/2 trials for the treatment of hematological cancer and solid tumors. The Company’s validated, proprietary F.I.R.S.T™ technology platform identifies both targets and the antibodies that bind to them, generating many promising new immune-modulatory drug candidates to fuel the Company’s own clinical development pipeline and providing licensing and partnering opportunities.The Company generates revenues from research collaborations and license agreements with multiple top-tier pharmaceutical companies, as well as from producing antibodies for third parties in the Company’s fully integrated manufacturing unit. More information is available at <a rel="noopener" href="http://www.bioinvent.com/">www.bioinvent.com</a>. Follow us on the social media platform X: @BioInvent.For further information, please contact: Cecilia Hofvander Senior Director Investor Relations +46 (0)46 286 85 50 <a rel="noopener" href="mailto:cecilia.hofvander@bioinvent.com">cecilia.hofvander@bioinvent.com</a>BioInvent International AB (publ) Co. Reg. No.: 556537-7263 Visiting address: Ideongatan 1 Mailing address: 223 70 LUND Phone: +46 (0)46 286 85 50 <a rel="noopener" href="http://www.bioinvent.com/">www.bioinvent.com</a></div><div class="mfn-footer mfn-attachment mfn-attachment-general">Attachments<hr><a rel="noopener" href="https://storage.mfn.se/69f220be-bd73-45a7-b1f0-14acb937ed11/invitation-to-presentation-of-bioinvents-interim-report-january-september-2024.pdf" class="mfn-generated mfn-primary">Invitation to presentation of BioInvent’s Interim report January – September 2024</a></div>

Invitation to presentation of BioInvent’s Interim report January – September 2024

Return on capital (ROE, ROI, ROIC, RONIC)

What does negative working capital mean and why is it a good thing?

Drug development investment: Value creation through M&As and licensing agreements

Income statement

Amazon continues to grow in Sweden

Beställ vårt nyhetsbrev — inget användarkonto krävs!